Letters to HCPs

Important information for Healthcare Professionals

Lemtrada (alemtuzumab) – Direct Healthcare Professional Communication – Restriction of use due to serious safety concerns

LEMTRADA ▼ (alemtuzumab): Restricted indication, additional contraindications and risk minimisation measures EMA has reviewed the benefit-risk balance of Lemtrada in light of new findings of serious, sometimes fatal adverse reactions reported during postmarketing use. New restrictions on its use have been introduced to replace previous interim measures. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

For Healthcare Professionals